HRP20210775T1 - Predlijekovi fenolnih agonista trpv1 - Google Patents
Predlijekovi fenolnih agonista trpv1 Download PDFInfo
- Publication number
- HRP20210775T1 HRP20210775T1 HRP20210775TT HRP20210775T HRP20210775T1 HR P20210775 T1 HRP20210775 T1 HR P20210775T1 HR P20210775T T HRP20210775T T HR P20210775TT HR P20210775 T HRP20210775 T HR P20210775T HR P20210775 T1 HRP20210775 T1 HR P20210775T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- substituted
- image
- unsubstituted
- compound according
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- -1 -OH Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 150000001345 alkine derivatives Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005362 aryl sulfone group Chemical group 0.000 claims 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Spoj koji ima strukturu Formule (I):
[image]
naznačen time što:
Y je:
[image]
[image]
[image]
X je -N(R5)-;
n je cijeli broj od 1 do 10;
Z je -NR3R4 ili -CO2H;
R5 je vodik, supstituiran ili nesupstituiran alkil, ili supstituiran ili nesupstituiran aril, i svaki R1 i R2 je svaki neovisno vodik, supstituiran ili nesupstituiran alkil, supstituiran ili nesupstituiran aril, ili supstituiran ili nesupstituiran acil, ili dvije R1 ili R2 skupine na susjednim ugljikovim atomima, zajedno s atomima ugljika na koje su oni vezani, tvore supstituiranu ili nesupstituiranu cikloalkilnu skupinu, ili R1 i R5 skupine na susjednim atomima, zajedno s atomima na koje su oni vezani, tvore supstituiranu ili nesupstituiranu heterocikloalkilnu skupinu; i
R3 i R4 je svaki neovisno vodik, supstituirani ili nesupstituirani alkil ili supstituirani ili nesupstituirani aril;
ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat;
pri čemu je supstituirana skupina supstituirana s jednom ili više skupina neovisno odabranih iz niza koji sadrži alkil, cikloalkil, aril, heteroaril, heterocikloalkil, -OH, alkoksi, ariloksi, alkiltio, ariltio, alkilsulfoksid, arilsulfoksid, alkilsulfon, arilsulfon, -CN, alkin, C1-C6alkilalkin, halo, acil, aciloksi, -CO2H, -CO2-alkil, nitro, haloalkil, fluoroalkil, fluoroalkoksi, i amino.
2. Spoj prema patentnom zahtjevu 1, naznačen time što Z je -NR3R4.
3. Spoj prema bilo kojem od patentnih zahtjeva 1-2, naznačen time što R3 je vodik i R4 je vodik ili supstituirani ili nesupstituirani alkil.
4. Spoj prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što R1 i R5 skupine na susjednim atomima, zajedno s atomima na koje su one vezane, tvore supstituiranu ili nesupstituiranu heterocikloalkilnu skupinu.
5. Spoj prema patentnom zahtjevu 4, naznačen time što je heterocikloalkilna skupina supstituirani ili nesupstituirani pirolidinski prsten, supstituirani ili nesupstituirani piperidinski prsten, ili supstituirani ili nesupstituirani piperazinski prsten.
6. Spoj prema patentnom zahtjevu 4, naznačen time što je heterocikloalkilna skupina nesupstituirani pirolidinski prsten, nesupstituirani piperidinski prsten ili nesupstituirani piperazinski prsten.
7. Spoj prema patentnom zahtjevu 4, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što ima strukturu:
[image]
8. Spoj prema patentnom zahtjevu 4, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što ima strukturu:
[image]
9. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što ima strukturu:
[image]
10. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što ima strukturu:
[image]
11. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što ima strukturu:
[image]
12. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što ima strukturu:
[image]
[image]
[image]
[image]
[image]
[image]
ili
[image]
13. Farmaceutski pripravak naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, farmaceutski prihvatljiv solvat ili hidrat, prema bilo kojem od zahtjeva 1-12, i farmaceutski prihvatljiv razrjeđivač, pomoćnu tvar ili vezivo.
14. Spoj prema bilo kojem od patentnih zahtjeva 1-12, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što je za uporabu u postupku terapije.
15. Spoj prema bilo kojem od patentnih zahtjeva 1-12, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv solvat ili hidrat, naznačen time što je za uporabu u postupku liječenja boli.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462084515P | 2014-11-25 | 2014-11-25 | |
US14/743,375 US9359316B1 (en) | 2014-11-25 | 2015-06-18 | Prodrugs of phenolic TRPV1 agonists |
PCT/US2015/062531 WO2016086063A1 (en) | 2014-11-25 | 2015-11-24 | Prodrugs of phenolic trpv1 agonists |
EP15863380.0A EP3223805B1 (en) | 2014-11-25 | 2015-11-24 | Prodrugs of phenolic trpv1 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210775T1 true HRP20210775T1 (hr) | 2021-06-25 |
Family
ID=56009519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210775TT HRP20210775T1 (hr) | 2014-11-25 | 2021-05-14 | Predlijekovi fenolnih agonista trpv1 |
Country Status (28)
Country | Link |
---|---|
US (1) | US9359316B1 (hr) |
EP (2) | EP3872063A1 (hr) |
JP (2) | JP6670841B2 (hr) |
KR (1) | KR102562571B1 (hr) |
CN (1) | CN107205961B (hr) |
AR (1) | AR102799A1 (hr) |
AU (1) | AU2015353532B2 (hr) |
BR (1) | BR112017010950B1 (hr) |
CA (1) | CA2968061C (hr) |
CY (1) | CY1124811T1 (hr) |
DK (1) | DK3223805T3 (hr) |
EA (1) | EA033619B1 (hr) |
ES (1) | ES2871095T3 (hr) |
HK (1) | HK1244672A1 (hr) |
HR (1) | HRP20210775T1 (hr) |
HU (1) | HUE054449T2 (hr) |
IL (1) | IL252307B (hr) |
LT (1) | LT3223805T (hr) |
MX (1) | MX2017006818A (hr) |
PH (1) | PH12017500974B1 (hr) |
PL (1) | PL3223805T3 (hr) |
PT (1) | PT3223805T (hr) |
RS (1) | RS61875B1 (hr) |
SG (1) | SG11201704290VA (hr) |
SI (1) | SI3223805T1 (hr) |
TW (1) | TWI692465B (hr) |
WO (1) | WO2016086063A1 (hr) |
ZA (1) | ZA201703409B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11634384B2 (en) | 2014-11-25 | 2023-04-25 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
EP3463576A4 (en) * | 2016-05-25 | 2020-01-15 | Concentric Analgesics, Inc. | PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA |
JP7100635B2 (ja) | 2016-11-02 | 2022-07-13 | セントレクシオン セラピューティクス コーポレイション | 安定な水性カプサイシン注射製剤およびその医学的使用 |
CN108069898B (zh) * | 2016-11-16 | 2021-11-23 | 南华大学 | 含烟酸辣椒碱酯衍生物、制备方法及其用途 |
WO2018217937A1 (en) * | 2017-05-24 | 2018-11-29 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
CA3069540A1 (en) | 2017-07-20 | 2019-01-24 | Centrexion Therapeutics Corporation | Methods and compositions for treatment of pain using capsaicin |
WO2020023793A1 (en) * | 2018-07-27 | 2020-01-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
EP3830078A4 (en) | 2018-07-27 | 2022-03-30 | Concentric Analgesics, Inc. | PEGYLATED PRODRUGS OF PHENOLIC TRPV1 AGONISTS |
US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
WO2021034863A1 (en) * | 2019-08-19 | 2021-02-25 | Chorda Pharma, Inc. | Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs |
WO2021063373A1 (zh) * | 2019-09-30 | 2021-04-08 | 南京清普生物科技有限公司 | 一种trpv1激动剂及其制备方法和用途 |
US20240058316A1 (en) * | 2020-12-14 | 2024-02-22 | Concentric Analgesics, Inc. | Prodrug of a phenolic trpv1 agonist for the treatment of pain |
AR124337A1 (es) * | 2020-12-14 | 2023-03-15 | Concentric Analgesics Inc | Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4151273A (en) | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
JPS624233A (ja) | 1985-07-01 | 1987-01-10 | Toyobo Co Ltd | 組織性プラスミノ−ゲン活性化因子の製造法 |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
DE3684446D1 (de) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | Arzneimittel mit verzoegerter stossweiser freisetzung. |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
US5094782A (en) * | 1990-12-24 | 1992-03-10 | National Science Council Of Republic Of China | Synthesis of capsacin derivatives and their use as an analgesic drug and vessel dilation drug |
WO1992018106A1 (en) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Method of manufacturing solid dispersion |
JPH0778037B2 (ja) * | 1991-06-13 | 1995-08-23 | ナショナル サイエンス カウンシル | カプサイシン誘導体又はその酸エステルを有効成分とする鎮痛剤、血管拡張剤 |
ATE195075T1 (de) | 1991-11-22 | 2000-08-15 | Procter & Gamble Pharma | Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
WO1998040070A1 (en) | 1997-03-13 | 1998-09-17 | Campbell James N | Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
AU2002219783A1 (en) * | 2000-10-10 | 2002-04-22 | Ortho-Mcneil Pharmaceutical, Inc. | Labeled resiniferatoxin derivatives for use in vanilloid receptor binding assay |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
US20050020690A1 (en) | 2002-12-18 | 2005-01-27 | Algorx | Infiltration of capsaicin into surgical sites and open wounds |
EP1587506B1 (en) | 2002-12-18 | 2008-07-23 | Algorx | Administration of capsaicinoids |
US20040202735A1 (en) * | 2003-04-08 | 2004-10-14 | Moore Bob M. | Method and kit for controlling bleeding |
US20080193481A1 (en) | 2005-03-14 | 2008-08-14 | Governors Of The University Of Alberta | Synthetic Anti-Candida Albicans Oligosaccharide Based Vaccines |
CN101208294A (zh) * | 2005-04-25 | 2008-06-25 | 纽罗吉斯克斯公司 | Trpv1激动剂化合物以及制备和使用它们的方法 |
US7943666B2 (en) | 2006-07-24 | 2011-05-17 | Trinity Laboratories, Inc. | Esters of capsaicin for treating pain |
CA2689310A1 (en) | 2007-05-30 | 2008-12-11 | Brigham Young University | Protein kinase-binding nucleosides and associated methods |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
CA2739078C (en) * | 2008-10-10 | 2017-01-03 | The Bionic Ear Institute | Biodegradable polymer - bioactive moiety conjugates |
CN101774938B (zh) * | 2010-01-20 | 2014-04-30 | 中国药科大学 | 一类辣椒碱衍生物、其制备方法及其制备新型镇痛药物的用途 |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
KR101478520B1 (ko) * | 2014-01-24 | 2015-01-02 | 동신대학교산학협력단 | 피부 안전성이 향상된 캡사이신-펩타이드 및 이를 이용한 피부 외용제 조성물 |
CN104447777B (zh) * | 2014-11-26 | 2016-09-14 | 浙江大学 | 一种辣椒碱-喜树碱类抗癌药物偶联物及其制备方法和应用 |
-
2015
- 2015-06-18 US US14/743,375 patent/US9359316B1/en active Active
- 2015-11-24 DK DK15863380.0T patent/DK3223805T3/da active
- 2015-11-24 SI SI201531607T patent/SI3223805T1/sl unknown
- 2015-11-24 WO PCT/US2015/062531 patent/WO2016086063A1/en active Application Filing
- 2015-11-24 SG SG11201704290VA patent/SG11201704290VA/en unknown
- 2015-11-24 ES ES15863380T patent/ES2871095T3/es active Active
- 2015-11-24 CA CA2968061A patent/CA2968061C/en active Active
- 2015-11-24 EA EA201790896A patent/EA033619B1/ru unknown
- 2015-11-24 AU AU2015353532A patent/AU2015353532B2/en active Active
- 2015-11-24 HU HUE15863380A patent/HUE054449T2/hu unknown
- 2015-11-24 KR KR1020177017437A patent/KR102562571B1/ko active IP Right Grant
- 2015-11-24 PT PT158633800T patent/PT3223805T/pt unknown
- 2015-11-24 EP EP21156331.7A patent/EP3872063A1/en not_active Withdrawn
- 2015-11-24 LT LTEP15863380.0T patent/LT3223805T/lt unknown
- 2015-11-24 EP EP15863380.0A patent/EP3223805B1/en active Active
- 2015-11-24 CN CN201580074440.4A patent/CN107205961B/zh active Active
- 2015-11-24 RS RS20210635A patent/RS61875B1/sr unknown
- 2015-11-24 PL PL15863380T patent/PL3223805T3/pl unknown
- 2015-11-24 MX MX2017006818A patent/MX2017006818A/es unknown
- 2015-11-24 BR BR112017010950-6A patent/BR112017010950B1/pt active IP Right Grant
- 2015-11-24 JP JP2017545881A patent/JP6670841B2/ja active Active
- 2015-11-25 TW TW104139294A patent/TWI692465B/zh active
- 2015-11-25 AR ARP150103868A patent/AR102799A1/es active IP Right Grant
-
2017
- 2017-05-16 IL IL252307A patent/IL252307B/en active IP Right Grant
- 2017-05-17 ZA ZA2017/03409A patent/ZA201703409B/en unknown
- 2017-05-25 PH PH12017500974A patent/PH12017500974B1/en unknown
-
2018
- 2018-03-22 HK HK18103987.9A patent/HK1244672A1/zh unknown
-
2020
- 2020-02-27 JP JP2020032357A patent/JP7026152B2/ja active Active
-
2021
- 2021-05-14 HR HRP20210775TT patent/HRP20210775T1/hr unknown
- 2021-05-24 CY CY20211100446T patent/CY1124811T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210775T1 (hr) | Predlijekovi fenolnih agonista trpv1 | |
HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
AR114941A1 (es) | Derivados de sulfonilurea | |
HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
AR123048A2 (es) | Moduladores de p2x7 | |
AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
CR20190168A (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
HRP20200478T1 (hr) | Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR109596A1 (es) | Compuestos pirazolopiridina y sus usos | |
AR109295A1 (es) | Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina | |
HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
RS54264B1 (en) | 4-ARYL-N-PHENYL-1,3,5-TRIAZINE-2-AMINES CONTAINING SULPHOXIMINE GROUP | |
UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
AR085602A1 (es) | Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes |